94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Daniele Generali1,2*
Rossana Berardi3Michele Caruso4Marina Cazzaniga5,6Ornella Garrone7Ida Minchella8Ida Paris9Carmine Pinto10Sabino De Placido11- 1Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy
- 2Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy
- 3Medical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, Italy
- 4Humanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, Italy
- 5School of Medicine and Surgery University of Milano Bicocca, Milan, Italy
- 6Phase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy
- 7Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- 8Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
- 9Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy
- 10Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy
- 11Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
A Corrigendum on
Aromatase inhibitors: the journey from the state of the art to clinical open questions
by Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C and De Placido S (2023) Front. Oncol. 13:1249160. doi: 10.3389/fonc.2023.1249160
In the published article, there was an error in affiliation 8. Instead of “Division of Early Drug Development, European Institute of Oncology, Milan, Italy”, it should be “Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: aromatase inhibitors, bone loss, cardiotoxicity, drug adherence, breast cancer
Citation: Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C and De Placido S (2024) Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions. Front. Oncol. 14:1369562. doi: 10.3389/fonc.2024.1369562
Received: 12 January 2024; Accepted: 15 January 2024;
Published: 23 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Generali, Berardi, Caruso, Cazzaniga, Garrone, Minchella, Paris, Pinto and De Placido. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniele Generali, ZGdlbmVyYWxpQHVuaXRzLml0